



Docket No.: 700953-045394-CPA-2-C

6  
A  
2/20/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 09/693,121  
Filed: 10/20/2000  
Inventors: Jeffrey Schlom and Dennis L. Panicali  
Title: GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)

Examiner: Yaen, C.H.  
Group: 1642

TECH CENTER 1600/2900

FEB 06 2002


RECEIVED

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

January 17, 2002  
Date

Nicole M. Gignac  
(type or print name of person mailing paper)

  
Signature of person mailing paper

Assistant Commissioner for Patents  
Washington, D.C. 20231

\*\*\*\*\*

RESPONSE TO RESTRICTION REQUIREMENT OF ELECTION OF SPECIES

Dear Sir:

In response to the Restriction Requirement dated December 18, 2001, Applicants elect Group II without traverse. With regard to the election of species, Applicants elect avipox/canary pox and RIBI Detox as the adjuvants.

Please cancel claims 1 – 16 without prejudice.

Please add new claims 17 – 29 as follows:

- A1
17. A method for generating an immune response to prostate-specific antigen (PSA) in a host, comprising, contacting the host with a [sufficient amount] of PSA or a [cytotoxic T-cell eliciting epitope thereof] and an [effective amount] of a cytokine or co-stimulatory molecule.

Serial No.: 09/693,121

Filed: 10/20/2000

Inventors: Jeffrey Schlom and Dennis L. Panicali

Title: GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)

Examiner:

Yaen, C.H.

Group: 1642

- Sub B1
18. The method of claim 17, further comprising at at least one periodic interval thereafter contacting the host with additional PSA or a cytotoxic T-cell eliciting epitope thereof.
19. The method of claim 18, wherein the host is contacted with the additional PSA by introducing a pox virus vector to the host having at least one insertion site containing a DNA segment encoding PSA or a cytotoxic T-cell eliciting epitope thereof operably linked to a promoter capable of expression in the host.
20. The method of claim 19, wherein the pox virus is selected from the group of pox viruses consisting of suipox, avipox, capripox and orthopox virus.
21. The method of claim 20, wherein the orthopox virus is vaccinia.
- A1
22. The method of claim 20, wherein the <sup>x NE swpl</sup> avipox is fowlpox, canary pox and pigeon pox.
23. The method of claim 20, wherein the suipox is swinepox.
24. The method of claim 17, wherein the PSA or T-cell eliciting epitope is formulated with an adjuvant or is in a liposomal formulation.
25. The method of claim 24, wherein the adjuvant is selected from the group consisting of RIBI Detox, QS21 and incomplete Freund's adjuvant.
26. The method of claim 17, wherein the cytokine is selected from the group consisting of IL-2, IL-6 or IL-12.
27. The method of claim 17, wherein the costimulatory molecule is selected from the group consisting of B7.1 or B7.2.
28. The method of claim 18, further comprising contacting the host with additional cytokine or co-stimulatory molecule.
- Sub B2
29. The method of claim 18, wherein the pox vector further contains a DNA encoding a cytokine or co-stimulatory molecule.